dextromethorphan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
opioid receptor antagonists/agonists, morphinan derivates 842 125-71-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dextromethorphan HBr
  • dextromethorphan hydrochloride
  • dextromethorphan hydrobromide hydrate
  • dextromethorphan
  • (+)-Dextromethorphan
  • d-Methorphan
  • dextromethorphan hydrobromide
  • dextromethorphan hydriodide
  • dextromethorphan hydrobromide monohydrate
  • dextromethorphan polistirex
Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.
  • Molecular weight: 271.40
  • Formula: C18H25NO
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -4.50
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O
90 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 15 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.19 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.88 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 11 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 0.24 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1957 FDA ANI PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 2354.78 10.23 5663 492864 241587 62748908
Completed suicide 2266.17 10.23 4084 494443 141589 62848906
Infusion related reaction 862.75 10.23 4015 494512 241506 62748989
Exposure to toxic agent 862.21 10.23 541 497986 5046 62985449
Sinusitis 686.21 10.23 3553 494974 223100 62767395
Muscle injury 560.97 10.23 1441 497086 63904 62926591
Folliculitis 547.17 10.23 1495 497032 68822 62921673
Acute hepatic failure 501.64 10.23 668 497859 17659 62972836
Irritable bowel syndrome 485.57 10.23 1588 496939 80824 62909671
Lower respiratory tract infection 466.32 10.23 2167 496360 130140 62860355
Intentional overdose 455.09 10.23 1449 497078 72703 62917792
Blood pressure fluctuation 421.07 10.23 1044 497483 45273 62945222
Blister 397.14 10.23 2042 496485 127772 62862723
Overdose 381.55 10.23 1852 496675 113226 62877269
Sleep disorder due to general medical condition, insomnia type 380.35 10.23 1084 497443 51133 62939362
Duodenal ulcer perforation 375.09 10.23 1517 497010 85692 62904803
Helicobacter infection 373.93 10.23 1582 496945 91203 62899292
Ill-defined disorder 370.00 10.23 1445 497082 80310 62910185
Injection site pain 367.77 10.23 288 498239 129512 62860983
Intentional product misuse 349.97 10.23 1164 497363 59753 62930742
Anti-cyclic citrullinated peptide antibody positive 336.79 10.23 1801 496726 114411 62876084
Pericarditis 336.78 10.23 1972 496555 129607 62860888
Impaired healing 316.32 10.23 1617 496910 100925 62889570
Nasopharyngitis 314.74 10.23 3215 495312 251042 62739453
Rheumatoid arthritis 307.78 10.23 3196 495331 250623 62739872
Metabolic acidosis 301.77 10.23 908 497619 44161 62946334
Hepatic enzyme increased 295.68 10.23 2650 495877 199678 62790817
Hepatic cytolysis 286.24 10.23 468 498059 14939 62975556
Product dose omission issue 280.32 10.23 924 497603 233389 62757106
Joint swelling 249.67 10.23 3783 494744 323883 62666612
Therapeutic product effect decreased 234.21 10.23 2433 496094 190754 62799741
Analgesic drug level increased 231.23 10.23 173 498354 2199 62988296
Hepatotoxicity 220.05 10.23 716 497811 36325 62954170
Intentional product use issue 218.99 10.23 1736 496791 126156 62864339
Device expulsion 218.63 10.23 14 498513 34908 62955587
Injection site erythema 216.62 10.23 200 498327 82974 62907521
Gastrointestinal disorder 214.71 10.23 1763 496764 129476 62861019
Diarrhoea 213.37 10.23 4149 494378 711217 62279278
Synovitis 208.85 10.23 2316 496211 184602 62805893
Anion gap 206.91 10.23 129 498398 1188 62989307
Medication error 192.63 10.23 868 497659 51416 62939079
Stomatitis 192.36 10.23 1797 496730 136928 62853567
Hypersensitivity 189.51 10.23 3290 495237 289395 62701100
Discomfort 182.92 10.23 2065 496462 165309 62825186
Weight increased 182.90 10.23 2970 495557 257822 62732673
Hand deformity 182.33 10.23 1985 496542 157472 62833023
Wrong technique in product usage process 179.45 10.23 136 498391 62204 62928291
Depressed level of consciousness 173.59 10.23 953 497574 61125 62929370
Psoriasis 171.95 10.23 260 498267 86697 62903798
Body temperature increased 169.49 10.23 659 497868 36533 62953962
Anaemia 161.33 10.23 1499 497028 291931 62698564
Swelling 161.16 10.23 3047 495480 272331 62718164
Drug ineffective 159.87 10.23 6650 491877 1038115 61952380
Wound 156.68 10.23 1965 496562 161298 62829197
Suicide attempt 151.20 10.23 906 497621 60012 62930483
Sedation complication 146.67 10.23 331 498196 13491 62977004
Injection site reaction 145.09 10.23 147 498380 58377 62932118
Infusion site pain 143.62 10.23 371 498156 16498 62973997
Blood pressure systolic abnormal 138.09 10.23 317 498210 13069 62977426
Blood pressure diastolic abnormal 135.51 10.23 331 498196 14211 62976284
Heart rate decreased 134.54 10.23 710 497817 44850 62945645
Injection site bruising 130.44 10.23 84 498443 41826 62948669
Injection site pruritus 129.11 10.23 99 498428 45017 62945478
Rheumatic fever 125.36 10.23 669 497858 42442 62948053
Creatinine renal clearance decreased 125.03 10.23 345 498182 15963 62974532
Respiratory arrest 124.79 10.23 548 497979 32097 62958398
Rheumatoid factor positive 123.32 10.23 1106 497421 83300 62907195
Peripheral swelling 122.68 10.23 2842 495685 263100 62727395
Coagulopathy 120.10 10.23 395 498132 20149 62970346
Cardio-respiratory arrest 119.59 10.23 844 497683 59115 62931380
Infusion site extravasation 118.90 10.23 257 498270 10169 62980326
Infection 118.34 10.23 2489 496038 226684 62763811
Blood pressure diastolic decreased 118.22 10.23 420 498107 22286 62968209
Neutropenia 118.07 10.23 846 497681 174159 62816336
Infusion site swelling 117.39 10.23 246 498281 9524 62980971
Confusional state 112.71 10.23 2538 495989 233842 62756653
Disease progression 112.37 10.23 538 497989 122220 62868275
Ear pain 111.58 10.23 570 497957 35548 62954947
Blood pressure systolic increased 110.72 10.23 694 497833 46703 62943792
Poisoning deliberate 110.62 10.23 261 498266 10957 62979538
Throat irritation 101.26 10.23 572 497955 37075 62953420
Injection site swelling 100.19 10.23 136 498391 47436 62943059
Cardiac failure congestive 100.02 10.23 380 498147 92053 62898442
Swollen joint count increased 99.77 10.23 552 497975 35502 62954993
Drug abuse 99.24 10.23 937 497590 71581 62918914
Oxygen saturation decreased 96.25 10.23 1092 497435 87493 62903002
Myocardial infarction 96.03 10.23 430 498097 99463 62891032
Blood pressure increased 94.93 10.23 1794 496733 160268 62830227
Hospitalisation 94.52 10.23 346 498181 84735 62905760
Osteonecrosis of jaw 93.16 10.23 83 498444 35040 62955455
Muscle spasticity 92.73 10.23 378 498149 21416 62969079
Nausea 91.50 10.23 5639 492888 848832 62141663
Drug resistance 91.10 10.23 33 498494 22900 62967595
Blood calcium decreased 89.93 10.23 429 498098 26022 62964473
Therapy cessation 89.51 10.23 65 498462 30392 62960103
Infusion site erythema 89.46 10.23 247 498280 11432 62979063
Neuropathy peripheral 86.96 10.23 529 497998 113138 62877357
Cardiac failure 84.91 10.23 385 498142 88757 62901738
Drug hypersensitivity 84.68 10.23 1827 496700 308860 62681635
Glossodynia 84.08 10.23 1917 496610 176959 62813536
Infusion site pruritus 83.31 10.23 161 498366 5874 62984621
Product substitution issue 83.13 10.23 13 498514 15983 62974512
Malignant neoplasm progression 82.90 10.23 347 498180 81774 62908721
Pancytopenia 82.88 10.23 435 498092 96498 62893997
Poisoning 81.51 10.23 265 498262 13435 62977060
Dizziness 80.53 10.23 2668 495859 427257 62563238
Pyroglutamic acidosis 79.63 10.23 54 498473 581 62989914
White blood cell count decreased 79.20 10.23 704 497823 138400 62852095
Drug interaction 78.61 10.23 1295 497232 227836 62762659
Acute lung injury 78.19 10.23 78 498449 1493 62989002
Pruritus 78.02 10.23 3527 495000 357926 62632569
Device dislocation 77.99 10.23 53 498474 25652 62964843
Respiratory depression 77.76 10.23 261 498266 13454 62977041
Product quality issue 75.05 10.23 103 498424 35762 62954733
Decreased appetite 74.10 10.23 1457 497070 249595 62740900
Sopor 73.78 10.23 41 498486 22123 62968372
Hepatic failure 73.49 10.23 506 498021 35150 62955345
Bone marrow failure 73.24 10.23 73 498454 29217 62961278
Arthropathy 72.46 10.23 2383 496144 232409 62758086
Device malfunction 72.12 10.23 25 498502 17832 62972663
Feeling abnormal 71.89 10.23 781 497746 147611 62842884
Therapeutic product effect incomplete 71.59 10.23 632 497895 124424 62866071
Coma 71.52 10.23 797 497730 63567 62926928
Abortion spontaneous 71.31 10.23 166 498361 47029 62943466
Injection site warmth 71.18 10.23 16 498511 15179 62975316
Pemphigus 70.84 10.23 1917 496610 181809 62808686
Pyrexia 70.67 10.23 4437 494090 466041 62524454
Paraesthesia 70.23 10.23 841 497686 156125 62834370
Mobility decreased 70.16 10.23 1339 497188 119820 62870675
Diabetes mellitus 69.47 10.23 216 498311 55594 62934901
Neoplasm progression 69.06 10.23 112 498415 36316 62954179
COVID-19 68.61 10.23 1259 497268 111844 62878651
Suspected suicide 68.25 10.23 156 498371 6412 62984083
Poor venous access 68.18 10.23 263 498264 14522 62975973
Orthostatic hypotension 68.05 10.23 502 498025 35658 62954837
Exposure via ingestion 66.12 10.23 97 498430 2812 62987683
Muscle spasms 65.95 10.23 847 497680 155303 62835192
Hepatic necrosis 65.79 10.23 141 498386 5546 62984949
Contusion 64.98 10.23 1590 496937 148454 62842041
Cerebrovascular accident 64.02 10.23 541 497986 107483 62883012
Contraindicated product administered 63.59 10.23 2195 496332 215453 62775042
Renal impairment 63.06 10.23 420 498107 87935 62902560
Surgery 62.98 10.23 116 498411 35796 62954699
Product storage error 62.04 10.23 20 498507 14936 62975559
Cognitive disorder 61.95 10.23 691 497836 55124 62935371
Pyroglutamate increased 61.34 10.23 40 498487 401 62990094
Night sweats 60.56 10.23 618 497909 48196 62942299
Bone pain 59.51 10.23 224 498303 54417 62936078
Injection site rash 59.49 10.23 37 498490 18772 62971723
Accidental overdose 59.31 10.23 349 498178 22960 62967535
Palmar-plantar erythrodysaesthesia syndrome 59.13 10.23 56 498471 22959 62967536
Infusion site bruising 58.84 10.23 107 498420 3725 62986770
Vision blurred 58.78 10.23 451 498076 91473 62899022
Red blood cell sedimentation rate abnormal 58.41 10.23 42 498485 19740 62970755
Electric shock 57.49 10.23 61 498466 1259 62989236
Blood cholesterol increased 56.08 10.23 1044 497483 92988 62897507
Respiratory disorder 55.98 10.23 510 498017 38572 62951923
Device difficult to use 55.09 10.23 16 498511 12780 62977715
Sedation 54.86 10.23 505 498022 38304 62952191
No adverse event 54.59 10.23 156 498371 41249 62949246
Infusion site haemorrhage 54.19 10.23 122 498405 4964 62985531
Therapy interrupted 54.15 10.23 108 498419 32347 62958148
Ear pruritus 53.78 10.23 105 498422 3860 62986635
Anion gap abnormal 53.66 10.23 36 498491 380 62990115
Seizure 53.24 10.23 727 497800 131907 62858588
Injection site urticaria 53.00 10.23 22 498505 14051 62976444
Hyperkalaemia 52.87 10.23 232 498295 53971 62936524
Injection site haemorrhage 52.73 10.23 68 498459 24246 62966249
Heart rate increased 52.68 10.23 1036 497491 93202 62897293
Type 2 diabetes mellitus 52.61 10.23 748 497779 63120 62927375
Leukopenia 51.41 10.23 375 498152 76915 62913580
Platelet count decreased 50.84 10.23 625 497902 115497 62874998
Dehydration 50.83 10.23 1007 497520 172347 62818148
Injection site mass 50.79 10.23 43 498484 18613 62971882
Blood parathyroid hormone decreased 50.78 10.23 8 498519 9783 62980712
Arthralgia 50.65 10.23 5160 493367 564550 62425945
Device issue 50.06 10.23 68 498459 23713 62966782
Thrombocytopenia 49.62 10.23 861 497666 150296 62840199
Multiple sclerosis relapse 49.44 10.23 204 498323 48274 62942221
Drug intolerance 49.05 10.23 2926 495601 305735 62684760
Depression 48.52 10.23 1173 497354 195319 62795176
Heart rate irregular 47.88 10.23 321 498206 22100 62968395
Oedema peripheral 47.71 10.23 1128 497399 188383 62802112
Epistaxis 47.34 10.23 355 498172 72370 62918125
Transient ischaemic attack 47.06 10.23 146 498381 37607 62952888
Liver injury 46.77 10.23 701 497826 59819 62930676
Schizoaffective disorder 46.71 10.23 93 498434 3469 62987026
Hypokalaemia 46.47 10.23 556 497971 103248 62887247
Hyponatraemia 46.12 10.23 610 497917 111290 62879205
Blood pressure diastolic increased 46.11 10.23 178 498349 9832 62980663
Product prescribing error 46.02 10.23 85 498442 26204 62964291
Drug use disorder 45.96 10.23 113 498414 4871 62985624
Systemic lupus erythematosus 45.94 10.23 2043 496484 206875 62783620
Jaundice cholestatic 45.69 10.23 144 498383 7180 62983315
Gastrointestinal haemorrhage 45.67 10.23 412 498115 80764 62909731
Foetal exposure during pregnancy 45.47 10.23 116 498411 31846 62958649
Accidental exposure to product 45.03 10.23 92 498435 27313 62963182
Dry skin 44.94 10.23 262 498265 56625 62933870
Myalgia 43.91 10.23 848 497679 145681 62844814
Suicidal ideation 43.89 10.23 298 498229 62123 62928372
Myelosuppression 43.88 10.23 74 498453 23629 62966866
Dyspnoea exertional 43.85 10.23 285 498242 60017 62930478
Hypocalcaemia 43.66 10.23 117 498410 31596 62958899
Granuloma skin 43.52 10.23 7 498520 8430 62982065
Basal cell carcinoma 42.65 10.23 98 498429 27893 62962602
Breast cancer stage I 42.42 10.23 3 498524 6886 62983609
Rash pruritic 42.29 10.23 285 498242 59514 62930981
Full blood count abnormal 42.18 10.23 119 498408 31598 62958897
Hyperlipidaemia 42.17 10.23 55 498472 19516 62970979
Hypomania 41.85 10.23 127 498400 6203 62984292
Urine leukocyte esterase positive 41.70 10.23 89 498438 3490 62987005
Hypercalcaemia 41.68 10.23 101 498426 28221 62962274
Unevaluable event 41.49 10.23 235 498292 51151 62939344
Full blood count decreased 41.38 10.23 89 498438 25935 62964560
Interstitial lung disease 41.35 10.23 300 498227 61608 62928887
Body temperature decreased 41.07 10.23 287 498240 20032 62970463
Cytokine release syndrome 40.83 10.23 221 498306 14093 62976402
Methaemoglobinaemia 40.64 10.23 70 498457 2333 62988162
Myelodysplastic syndrome 40.48 10.23 43 498484 16711 62973784
Posterior reversible encephalopathy syndrome 40.27 10.23 46 498481 17299 62973196
Syncope 40.02 10.23 664 497863 116721 62873774
Mucosal inflammation 39.87 10.23 211 498316 46717 62943778
Breast cancer female 39.76 10.23 29 498498 13530 62976965
Tremor 39.71 10.23 765 497762 131474 62859021
Atrial fibrillation 39.69 10.23 660 497867 115976 62874519
Visual acuity reduced 39.62 10.23 69 498458 21757 62968738
Drug withdrawal syndrome 39.22 10.23 98 498429 27096 62963399
Weight fluctuation 39.18 10.23 167 498360 9652 62980843
Osteonecrosis 38.92 10.23 84 498443 24446 62966049
Incorrect drug administration rate 38.87 10.23 92 498435 3870 62986625
Pain in extremity 38.73 10.23 2168 496359 329318 62661177
Loss of consciousness 38.38 10.23 674 497853 117447 62873048
Skin necrosis 38.17 10.23 32 498495 13918 62976577
Haematotoxicity 38.08 10.23 13 498514 9363 62981132
Renal failure 38.02 10.23 672 497855 116980 62873515
Therapeutic response decreased 37.86 10.23 305 498222 61220 62929275
Urine abnormality 37.54 10.23 131 498396 6888 62983607
Acute kidney injury 37.49 10.23 1688 496839 261727 62728768
Crystal urine present 37.37 10.23 55 498472 1599 62988896
Blood glucose increased 37.34 10.23 449 498078 83307 62907188
Injection site induration 37.12 10.23 13 498514 9213 62981282
Inappropriate schedule of product administration 37.02 10.23 1074 497453 102891 62887604
Administration site swelling 36.31 10.23 48 498479 1259 62989236
Memory impairment 36.12 10.23 588 497939 103670 62886825
Injury 35.95 10.23 790 497737 72457 62918038
Coronary artery disease 35.73 10.23 132 498395 32245 62958250
Panniculitis 35.18 10.23 23 498504 11362 62979133
Hypotension 35.14 10.23 2539 495988 270065 62720430
Underdose 35.06 10.23 105 498422 27351 62963144
Epilepsy 34.93 10.23 103 498424 26962 62963533
Anticipatory anxiety 34.84 10.23 46 498481 1205 62989290
White blood cells urine positive 34.58 10.23 104 498423 5054 62985441
Vaginal haemorrhage 34.47 10.23 106 498421 27381 62963114
Macular degeneration 34.35 10.23 317 498210 24059 62966436
Fall 34.27 10.23 2634 495893 389700 62600795
Hypertensive crisis 33.93 10.23 42 498485 15244 62975251
Pulmonary hypertension 33.77 10.23 163 498364 36960 62953535
Gastrooesophageal reflux disease 33.59 10.23 538 497989 95101 62895394
Therapeutic response unexpected 33.42 10.23 60 498467 18699 62971796
Metastases to bone 33.33 10.23 72 498455 20947 62969548
Respiratory rate increased 33.22 10.23 202 498325 13446 62977049
Femur fracture 33.15 10.23 192 498335 41564 62948931
Diabetic ketoacidosis 32.71 10.23 70 498457 20435 62970060
Alanine aminotransferase increased 32.67 10.23 1056 497471 102714 62887781
Extrapyramidal disorder 32.20 10.23 34 498493 13250 62977245
Spinal stenosis 32.10 10.23 42 498485 14883 62975612
Drug-induced liver injury 31.90 10.23 468 498059 39754 62950741
Genital haemorrhage 31.87 10.23 9 498518 7323 62983172
Burning sensation 31.54 10.23 274 498253 54133 62936362
Device use error 31.54 10.23 4 498523 5757 62984738
Skin exfoliation 31.19 10.23 204 498323 42898 62947597
Multiple drug therapy 30.84 10.23 80 498447 3566 62986929
Lactic acidosis 30.42 10.23 176 498351 38111 62952384
Haemorrhage 30.40 10.23 319 498208 60703 62929792
International normalised ratio increased 30.34 10.23 523 498004 45902 62944593
Breast cancer 30.16 10.23 239 498288 48144 62942351
Fluid retention 30.15 10.23 311 498216 59375 62931120
Urticaria 30.04 10.23 1591 496936 164211 62826284
Infusion site mass 29.57 10.23 56 498471 2012 62988483
Palpitations 29.54 10.23 667 497860 112103 62878392
Administration site pain 29.54 10.23 35 498492 819 62989676
Urinary sediment present 29.47 10.23 58 498469 2145 62988350
Pathogen resistance 29.44 10.23 7 498520 6391 62984104
Ageusia 29.15 10.23 39 498488 13689 62976806
Ascites 28.85 10.23 194 498333 40534 62949961
Neurotoxicity 28.80 10.23 56 498471 16934 62973561
Complication associated with device 28.75 10.23 56 498471 16922 62973573
Gestational diabetes 28.72 10.23 15 498512 8381 62982114
Infusion site nodule 28.63 10.23 46 498481 1446 62989049
Disease recurrence 28.55 10.23 118 498409 27912 62962583
Electrolyte imbalance 28.45 10.23 73 498454 20003 62970492
Chronic kidney disease 28.42 10.23 224 498303 45174 62945321
Injection site discolouration 28.40 10.23 13 498514 7835 62982660
Metastases to lung 28.34 10.23 35 498492 12715 62977780
Cytomegalovirus infection 28.31 10.23 78 498449 20874 62969621
Heavy menstrual bleeding 28.08 10.23 61 498466 17712 62972783
Cerebral infarction 27.97 10.23 95 498432 23798 62966697
Transplant rejection 27.96 10.23 26 498501 10754 62979741
Facet joint syndrome 27.88 10.23 177 498350 11961 62978534
Hypothyroidism 27.79 10.23 208 498319 42424 62948071
Irritability 27.77 10.23 141 498386 31553 62958942
Metastases to liver 27.67 10.23 94 498433 23545 62966950
Second primary malignancy 27.52 10.23 14 498513 7939 62982556
Intervertebral discitis 27.48 10.23 71 498456 3157 62987338
Hyperglycaemia 27.42 10.23 204 498323 41663 62948832
Toxicologic test abnormal 27.37 10.23 31 498496 690 62989805
Prothrombin time shortened 27.27 10.23 53 498474 1942 62988553
Infusion site irritation 27.15 10.23 35 498492 895 62989600
Drug dose omission by device 27.11 10.23 3 498524 4798 62985697
Respiratory failure 27.10 10.23 601 497926 101257 62889238
Disturbance in attention 27.00 10.23 182 498345 38007 62952488
Blood potassium decreased 26.94 10.23 206 498321 41820 62948675
Premature delivery 26.94 10.23 134 498393 30147 62960348
Thrombotic microangiopathy 26.77 10.23 26 498501 10535 62979960
Soft tissue disorder 26.72 10.23 86 498441 4336 62986159
Complication of device insertion 26.65 10.23 13 498514 7551 62982944
Sepsis 26.54 10.23 959 497568 152164 62838331
Labelled drug-drug interaction medication error 26.53 10.23 40 498487 13359 62977136
Neutrophil percentage increased 26.37 10.23 66 498461 2877 62987618
COVID-19 pneumonia 26.02 10.23 196 498331 14013 62976482
Cardiac disorder 25.99 10.23 264 498263 50552 62939943
Anion gap increased 25.72 10.23 50 498477 1832 62988663
Fear of injection 25.72 10.23 12 498515 7152 62983343
Pulmonary arterial hypertension 25.60 10.23 91 498436 22486 62968009
Rash 25.59 10.23 4885 493642 555986 62434509
Acute myocardial infarction 25.34 10.23 148 498379 31976 62958519
Specific gravity urine decreased 25.33 10.23 31 498496 751 62989744
Thrombosis 25.23 10.23 357 498170 64398 62926097
Fibromyalgia 25.21 10.23 818 497709 79602 62910893
Gait disturbance 25.20 10.23 1178 497349 182000 62808495
Bursitis 25.19 10.23 420 498107 36621 62953874
Withdrawal syndrome 25.16 10.23 77 498450 19920 62970575
Septic shock 25.03 10.23 370 498157 66259 62924236
Dysgeusia 25.01 10.23 240 498287 46470 62944025
Akathisia 25.00 10.23 21 498506 9125 62981370
Complication of device removal 24.93 10.23 5 498522 5137 62985358
Skin ulcer 24.85 10.23 217 498310 42828 62947667
Red blood cells urine positive 24.83 10.23 67 498460 3059 62987436
Polyneuropathy 24.81 10.23 48 498479 14541 62975954
Lymphocyte percentage decreased 24.74 10.23 65 498462 2920 62987575
Sensitivity to weather change 24.65 10.23 13 498514 7224 62983271
Pneumocystis jirovecii pneumonia 24.36 10.23 61 498466 16853 62973642
Musculoskeletal disorder 24.22 10.23 82 498445 20562 62969933
Post transplant lymphoproliferative disorder 24.17 10.23 5 498522 5026 62985469
Hepatic cirrhosis 24.04 10.23 106 498421 24628 62965867
Sexual dysfunction 23.93 10.23 3 498524 4356 62986139
Tardive dyskinesia 23.89 10.23 19 498508 8483 62982012
Incorrect dose administered by device 23.85 10.23 3 498524 4345 62986150
Systemic infection 23.74 10.23 4 498523 4656 62985839
Aphasia 23.47 10.23 157 498370 32843 62957652
Ear infection 23.37 10.23 426 498101 37787 62952708
Lymphocyte count decreased 23.19 10.23 350 498177 29907 62960588
Intermenstrual bleeding 23.18 10.23 17 498510 7909 62982586
Ventricular extrasystoles 23.03 10.23 35 498492 11652 62978843
Infusion site discomfort 23.00 10.23 41 498486 1405 62989090
Neuroleptic malignant syndrome 22.91 10.23 37 498490 12019 62978476
Renal disorder 22.89 10.23 158 498369 32816 62957679
Hypocoagulable state 22.87 10.23 37 498490 1170 62989325
Multiple allergies 22.85 10.23 186 498341 13616 62976879
Hepatitis acute 22.85 10.23 136 498391 8984 62981511
Thinking abnormal 22.84 10.23 30 498497 10613 62979882
Product complaint 22.79 10.23 41 498486 12768 62977727
Deep vein thrombosis postoperative 22.64 10.23 160 498367 11209 62979286
Hepatic encephalopathy 22.59 10.23 159 498368 11123 62979372
Infusion site rash 22.56 10.23 49 498478 1945 62988550
Vital capacity decreased 22.52 10.23 45 498482 1683 62988812
Dermatitis atopic 22.35 10.23 26 498501 9698 62980797
Device breakage 22.33 10.23 35 498492 11507 62978988
Laboratory test abnormal 22.31 10.23 122 498405 26790 62963705
Cardiotoxicity 22.30 10.23 20 498507 8418 62982077
Carpal tunnel syndrome 22.23 10.23 86 498441 20731 62969764
Schizophrenia 22.17 10.23 144 498383 9808 62980687
Insurance issue 22.07 10.23 101 498426 6020 62984475
Product adhesion issue 22.04 10.23 5 498522 4714 62985781
Sputum culture positive 22.00 10.23 51 498476 2116 62988379
Metastases to lymph nodes 21.97 10.23 19 498508 8139 62982356
Abdominal distension 21.92 10.23 515 498012 86100 62904395
Cardiac arrest 21.88 10.23 912 497615 91633 62898862
Drug ineffective for unapproved indication 21.82 10.23 167 498360 33896 62956599
Forced expiratory volume decreased 21.78 10.23 6 498521 4962 62985533
Right ventricular failure 21.76 10.23 66 498461 17122 62973373
Substance abuse 21.75 10.23 85 498442 4722 62985773
Brain oedema 21.75 10.23 188 498339 14007 62976488
Rheumatoid nodule 21.62 10.23 66 498461 17089 62973406
Analgesic drug level above therapeutic 21.62 10.23 15 498512 168 62990327
Skin burning sensation 21.56 10.23 42 498485 12692 62977803
Drug level increased 21.49 10.23 273 498254 22463 62968032
Dyskinesia 21.40 10.23 155 498372 31847 62958648
Disturbance in social behaviour 21.31 10.23 3 498524 3990 62986505
Multiple-drug resistance 21.29 10.23 7 498520 5163 62985332
Body temperature fluctuation 21.28 10.23 52 498475 2233 62988262
Brain death 21.23 10.23 67 498460 3343 62987152
Abnormal dreams 21.21 10.23 31 498496 10485 62980010
Generalised tonic-clonic seizure 21.16 10.23 137 498390 28879 62961616
Acute myeloid leukaemia 20.89 10.23 67 498460 17080 62973415
Low density lipoprotein increased 20.81 10.23 12 498515 6345 62984150
Treatment noncompliance 20.74 10.23 190 498337 37135 62953360
Product preparation error 20.67 10.23 11 498516 6081 62984414
Acidosis 20.59 10.23 155 498372 11078 62979417
Low turnover osteopathy 20.44 10.23 4 498523 4181 62986314
Anti-cyclic citrullinated peptide antibody 20.41 10.23 106 498421 6652 62983843
Status epilepticus 20.37 10.23 57 498470 15176 62975319
Neutrophil count decreased 20.24 10.23 316 498211 56090 62934405
Fracture 20.22 10.23 82 498445 19502 62970993
Upper respiratory tract infection 20.19 10.23 812 497715 81235 62909260
Skin toxicity 20.10 10.23 6 498521 4708 62985787
Blood pH decreased 20.10 10.23 55 498472 2532 62987963
Pharyngeal paraesthesia 20.09 10.23 47 498480 1962 62988533
Sleep apnoea syndrome 20.02 10.23 140 498387 28993 62961502
Cerebral haemorrhage 19.99 10.23 150 498377 30579 62959916
Unintended pregnancy 19.76 10.23 12 498515 6167 62984328
Angina unstable 19.75 10.23 16 498511 7079 62983416
Caesarean section 19.75 10.23 68 498459 16964 62973531
Lip dry 19.73 10.23 197 498330 15273 62975222
Hepatitis cholestatic 19.49 10.23 106 498421 6772 62983723
Hallucination, auditory 19.45 10.23 45 498482 12779 62977716
Pain in jaw 19.45 10.23 233 498294 43263 62947232
Transplant dysfunction 19.37 10.23 7 498520 4865 62985630
Hypomagnesaemia 19.31 10.23 139 498388 28598 62961897
Unresponsive to stimuli 19.31 10.23 373 498154 33443 62957052
Amenorrhoea 19.24 10.23 30 498497 9884 62980611
Ductus arteriosus premature closure 19.20 10.23 18 498509 318 62990177
Blood creatine increased 19.15 10.23 91 498436 5510 62984985
Iron deficiency anaemia 19.15 10.23 86 498441 19883 62970612
Inappropriate antidiuretic hormone secretion 19.12 10.23 60 498467 15402 62975093
Administration site bruise 19.11 10.23 20 498507 406 62990089
X-ray abnormal 19.09 10.23 119 498408 7991 62982504
Infusion site urticaria 18.96 10.23 40 498487 1556 62988939
Disorientation 18.94 10.23 208 498319 39244 62951251
Deep vein thrombosis 18.85 10.23 507 498020 83293 62907202
Brain stem glioma 18.71 10.23 14 498513 178 62990317
Drug eruption 18.70 10.23 140 498387 28554 62961941
Plasma cell myeloma 18.58 10.23 186 498341 35719 62954776
Prothrombin time ratio decreased 18.53 10.23 22 498505 516 62989979
Macular oedema 18.33 10.23 4 498523 3873 62986622
Dystonia 18.26 10.23 52 498475 13767 62976728
Adjustment disorder with depressed mood 18.26 10.23 140 498387 10064 62980431
Galactorrhoea 18.25 10.23 5 498522 4150 62986345
Pregnancy with contraceptive device 18.23 10.23 7 498520 4687 62985808
Ankylosing spondylitis 18.21 10.23 34 498493 10440 62980055
Blood immunoglobulin E increased 18.13 10.23 4 498523 3845 62986650
Rheumatoid lung 18.13 10.23 4 498523 3844 62986651
Liver transplant 18.09 10.23 49 498478 2242 62988253
Malaise 18.04 10.23 2930 495597 413024 62577471
Haemophagocytic lymphohistiocytosis 18.04 10.23 35 498492 10592 62979903
Tinnitus 17.85 10.23 186 498341 35442 62955053
Hypothermia 17.83 10.23 174 498353 13407 62977088
Atypical femur fracture 17.79 10.23 10 498517 5362 62985133
Pulmonary embolism 17.76 10.23 742 497785 115942 62874553
Ventricular fibrillation 17.72 10.23 42 498485 11825 62978670
Oral discomfort 17.71 10.23 28 498499 9173 62981322
Pneumonia streptococcal 17.71 10.23 42 498485 1769 62988726
Haemoglobin decreased 17.60 10.23 948 497579 144537 62845958
Coagulation factor X level decreased 17.52 10.23 10 498517 77 62990418
Therapeutic response shortened 17.46 10.23 156 498371 11732 62978763
Flatulence 17.45 10.23 181 498346 34521 62955974
Wound infection 17.33 10.23 250 498277 21160 62969335
Diplopia 17.32 10.23 112 498415 23616 62966879
Cardiomyopathy 17.31 10.23 75 498452 17509 62972986
Mitral valve incompetence 17.26 10.23 87 498440 19507 62970988
Reversible airways obstruction 17.24 10.23 42 498485 1800 62988695
Torsade de pointes 17.09 10.23 51 498476 13300 62977195
Aplasia pure red cell 16.92 10.23 7 498520 4480 62986015
Peripheral venous disease 16.89 10.23 191 498336 15286 62975209
Post cholecystectomy syndrome 16.88 10.23 19 498508 420 62990075
Dysphoria 16.80 10.23 9 498518 4957 62985538
Dyspnoea 16.78 10.23 4783 493744 656530 62333965
Colorectal cancer 16.75 10.23 4 498523 3641 62986854
Renal failure neonatal 16.70 10.23 13 498514 176 62990319
Uterine perforation 16.68 10.23 18 498509 6945 62983550
Invasive ductal breast carcinoma 16.65 10.23 18 498509 6940 62983555
Pleural effusion 16.54 10.23 582 497945 92628 62897867
Tricuspid valve incompetence 16.53 10.23 59 498468 14562 62975933
Postmortem blood drug level increased 16.50 10.23 22 498505 582 62989913
SARS-CoV-2 test positive 16.41 10.23 114 498413 7942 62982553
Febrile bone marrow aplasia 16.39 10.23 20 498507 7305 62983190
Cryopyrin associated periodic syndrome 16.33 10.23 17 498510 343 62990152
Device leakage 16.28 10.23 19 498508 7077 62983418
Deafness 16.24 10.23 79 498448 17878 62972617
Ischaemic stroke 16.24 10.23 79 498448 17878 62972617
Ketoacidosis 16.24 10.23 7 498520 4371 62986124
Coagulation factor VII level decreased 16.23 10.23 10 498517 90 62990405
Aspergillus infection 16.18 10.23 24 498503 8069 62982426
Mood swings 16.09 10.23 81 498446 18167 62972328
Post procedural pulmonary embolism 16.00 10.23 15 498512 265 62990230
Joint range of motion decreased 15.98 10.23 350 498177 32078 62958417
Skin lesion 15.96 10.23 159 498368 30562 62959933
Haematuria 15.95 10.23 149 498378 29008 62961487
Abdominal pain lower 15.93 10.23 127 498400 25551 62964944
Congestive cardiomyopathy 15.93 10.23 15 498512 6167 62984328
Red cell distribution width increased 15.92 10.23 139 498388 10385 62980110
Pancreatic carcinoma 15.86 10.23 22 498505 7606 62982889
Vein collapse 15.84 10.23 29 498498 1015 62989480
Lupus-like syndrome 15.82 10.23 64 498463 15231 62975264
Vertigo 15.74 10.23 354 498173 59533 62930962
Autoimmune disorder 15.71 10.23 205 498322 16972 62973523
Embedded device 15.66 10.23 4 498523 3479 62987016
Skin discolouration 15.65 10.23 206 498321 37622 62952873
Cardiac failure acute 15.62 10.23 32 498495 9491 62981004
Thyroid neoplasm 15.60 10.23 6 498521 4013 62986482
Blood urine present 15.57 10.23 184 498343 14885 62975610
Dysphagia 15.52 10.23 554 497973 88031 62902464
Maternal exposure timing unspecified 15.45 10.23 102 498425 6985 62983510
Movement disorder 15.43 10.23 103 498424 21558 62968937
Product residue present 15.34 10.23 6 498521 3973 62986522
Polycystic ovaries 15.28 10.23 8 498519 4463 62986032
Aspartate aminotransferase 15.27 10.23 18 498509 419 62990076
Ventricular arrhythmia 15.19 10.23 65 498462 3763 62986732
Dislocation of vertebra 15.19 10.23 118 498409 8517 62981978
Gastrointestinal pain 15.08 10.23 34 498493 9742 62980753
Mood altered 15.05 10.23 62 498465 14681 62975814
Asthenia 15.04 10.23 2717 495810 380887 62609608
Band neutrophil count increased 15.02 10.23 17 498510 378 62990117
Epstein-Barr virus infection 15.02 10.23 25 498502 8025 62982470
Device failure 15.01 10.23 15 498512 5996 62984499
Enthesopathy 14.95 10.23 28 498499 8586 62981909
Aspartate aminotransferase increased 14.90 10.23 859 497668 89418 62901077
Osmolar gap 14.87 10.23 10 498517 106 62990389
Prothrombin time prolonged 14.83 10.23 127 498400 9437 62981058
Clostridium test positive 14.81 10.23 57 498470 3144 62987351
Sudden infant death syndrome 14.75 10.23 15 498512 294 62990201
Impaired quality of life 14.68 10.23 57 498470 13726 62976769
Bacterial test 14.62 10.23 30 498497 1144 62989351
Joint stiffness 14.54 10.23 236 498291 41633 62948862
Cardiovascular disorder 14.49 10.23 46 498481 11766 62978729
Speech disorder 14.44 10.23 228 498299 40401 62950094
Dysphonia 14.42 10.23 275 498252 47339 62943156
Dysstasia 14.41 10.23 102 498425 21064 62969431
Cytopenia 14.36 10.23 45 498482 11556 62978939
Sensory disturbance 14.27 10.23 57 498470 13615 62976880
Therapy change 14.26 10.23 16 498511 6065 62984430
Oral pruritus 14.25 10.23 45 498482 2246 62988249
Head injury 14.14 10.23 142 498385 27254 62963241
Congestive hepatopathy 14.11 10.23 53 498474 2889 62987606
Tendonitis 14.11 10.23 93 498434 19522 62970973
Metastases to central nervous system 14.09 10.23 54 498473 13051 62977444
White coat hypertension 13.96 10.23 22 498505 680 62989815
Haemoglobin urine present 13.95 10.23 24 498503 799 62989696
Osteoarthritis 13.94 10.23 609 497918 94734 62895761
Abortion induced 13.94 10.23 38 498489 10204 62980291
Drug screen positive 13.93 10.23 61 498466 3568 62986927
Device related thrombosis 13.92 10.23 38 498489 1747 62988748
Vaginal flatulence 13.91 10.23 57 498470 3236 62987259
Small for dates baby 13.91 10.23 6 498521 3745 62986750
Hip fracture 13.91 10.23 156 498371 29318 62961177
Granulocyte count increased 13.90 10.23 25 498502 863 62989632
Pre-eclampsia 13.89 10.23 32 498495 9101 62981394
Administration site erythema 13.89 10.23 23 498504 742 62989753
Drug level below therapeutic 13.79 10.23 75 498452 4791 62985704
Dysarthria 13.77 10.23 244 498283 42467 62948028
Dyslipidaemia 13.76 10.23 23 498504 7370 62983125
Coagulation factor decreased 13.74 10.23 9 498518 91 62990404
Snoring 13.66 10.23 8 498519 4194 62986301
Eosinophil percentage increased 13.66 10.23 27 498500 1002 62989493
Personality change 13.63 10.23 21 498506 6952 62983543
Psoriatic arthropathy 13.50 10.23 584 497943 90936 62899559
Device related infection 13.47 10.23 118 498409 23274 62967221
Accidental death 13.40 10.23 40 498487 1936 62988559
Osteomyelitis 13.38 10.23 135 498392 25885 62964610
Limb discomfort 13.35 10.23 159 498368 29557 62960938
Seasonal allergy 13.32 10.23 235 498292 20715 62969780
Device deployment issue 13.31 10.23 7 498520 3895 62986600
Eczema 13.30 10.23 176 498351 32115 62958380
Skin cancer 13.26 10.23 46 498481 11449 62979046
Anticholinergic syndrome 13.21 10.23 45 498482 2337 62988158
Immune reconstitution inflammatory syndrome 13.21 10.23 17 498510 6067 62984428
Coronary arterial stent insertion 13.21 10.23 3 498524 2826 62987669
Potentiating drug interaction 13.19 10.23 9 498518 4347 62986148
Cells in urine 13.18 10.23 12 498515 204 62990291
Hypersensitivity vasculitis 13.13 10.23 8 498519 4104 62986391
Allergy to chemicals 13.13 10.23 53 498474 2989 62987506
Bundle branch block left 13.10 10.23 22 498505 7037 62983458
Pelvic pain 13.10 10.23 58 498469 13461 62977034
Sleep disorder 13.06 10.23 774 497753 80792 62909703
Hallucination 13.03 10.23 329 498198 54488 62936007
Concomitant disease aggravated 13.01 10.23 33 498494 9079 62981416
Foot operation 13.00 10.23 23 498504 7208 62983287
Respiratory symptom 12.99 10.23 5 498522 3342 62987153
Intestinal haemorrhage 12.97 10.23 7 498520 3840 62986655
Asthma 12.97 10.23 845 497682 126716 62863779
COVID-19 immunisation 12.91 10.23 37 498490 1750 62988745
Thyroid cancer 12.90 10.23 15 498512 5596 62984899
Muscle disorder 12.87 10.23 12 498515 4957 62985538
Small fibre neuropathy 12.86 10.23 17 498510 446 62990049
Blood creatinine decreased 12.82 10.23 81 498446 5464 62985031
Product monitoring error 12.80 10.23 10 498517 4506 62985989
Supraventricular tachycardia 12.78 10.23 63 498464 14208 62976287
Uterine cancer 12.77 10.23 11 498516 4722 62985773
Haemorrhage intracranial 12.74 10.23 58 498469 13361 62977134
Ductus arteriosus stenosis foetal 12.72 10.23 11 498516 174 62990321
Pericardial effusion 12.69 10.23 163 498364 29895 62960600
Uterine leiomyoma 12.61 10.23 34 498493 9164 62981331
Patent ductus arteriosus 12.58 10.23 9 498518 4241 62986254
Body height decreased 12.54 10.23 39 498488 10039 62980456
Myelocyte count increased 12.53 10.23 15 498512 355 62990140
Product use in unapproved indication 12.52 10.23 1223 497304 177857 62812638
Mean cell haemoglobin concentration increased 12.50 10.23 18 498509 513 62989982
Fixed eruption 12.49 10.23 28 498499 1136 62989359
Shoulder arthroplasty 12.48 10.23 8 498519 3994 62986501
Prescribed overdose 12.47 10.23 354 498173 33799 62956696
Oesophageal stenosis 12.47 10.23 5 498522 3261 62987234
Renal papillary necrosis 12.46 10.23 13 498514 263 62990232
Blood triglycerides increased 12.45 10.23 53 498474 12435 62978060
Tongue disorder 12.43 10.23 42 498485 10538 62979957
Visual impairment 12.43 10.23 539 497988 83907 62906588
Exposure to SARS-CoV-2 12.40 10.23 36 498491 1715 62988780
Diffuse large B-cell lymphoma 12.38 10.23 21 498506 6691 62983804
Mental impairment 12.37 10.23 63 498464 14088 62976407
Oral pain 12.35 10.23 153 498374 28241 62962254
Lupus vulgaris 12.31 10.23 85 498442 5909 62984586
Glutathione decreased 12.31 10.23 6 498521 32 62990463
Agranulocytosis 12.27 10.23 132 498395 25002 62965493
Arrhythmia 12.26 10.23 218 498309 37922 62952573
Cardiac failure chronic 12.25 10.23 10 498517 4408 62986087
Administration site pruritus 12.24 10.23 14 498513 315 62990180
Suspected COVID-19 12.16 10.23 46 498481 2516 62987979
Multiple organ dysfunction syndrome 12.08 10.23 346 498181 56406 62934089
Large intestine polyp 12.07 10.23 29 498498 8128 62982367
Skin infection 12.07 10.23 175 498352 14827 62975668
Chest pain 12.05 10.23 1498 497029 214461 62776034
Pancreatitis 12.04 10.23 293 498234 48762 62941733
Injection site haematoma 12.04 10.23 22 498505 6810 62983685
Haematochezia 12.03 10.23 324 498203 53220 62937275
Opiates positive 12.02 10.23 15 498512 371 62990124
Lymphoproliferative disorder 11.99 10.23 5 498522 3185 62987310
Vitamin K deficiency 11.98 10.23 16 498511 424 62990071
Central nervous system lesion 11.97 10.23 43 498484 10592 62979903
Focal dyscognitive seizures 11.95 10.23 4 498523 2917 62987578
Dissociation 11.94 10.23 4 498523 2915 62987580
Inflammation 11.93 10.23 774 497753 81499 62908996
Injury associated with device 11.89 10.23 7 498520 3659 62986836
Pneumonia aspiration 11.89 10.23 195 498332 34345 62956150
Nail bed inflammation 11.83 10.23 15 498512 377 62990118
Blood loss anaemia 11.80 10.23 34 498493 8967 62981528
Product physical issue 11.79 10.23 13 498514 4967 62985528
Bronchopulmonary aspergillosis 11.78 10.23 32 498495 8603 62981892
Band neutrophil percentage increased 11.77 10.23 12 498515 236 62990259
Spinal pain 11.77 10.23 58 498469 13081 62977414
Anxiety 11.76 10.23 1512 497015 216029 62774466
Gastritis 11.74 10.23 214 498313 37089 62953406
Aortic valve incompetence 11.74 10.23 18 498509 5970 62984525
Drug tolerance 11.70 10.23 23 498504 6926 62983569
Lymphadenopathy 11.68 10.23 222 498305 38236 62952259
Smear cervix abnormal 11.67 10.23 50 498477 2896 62987599
Obstructive airways disorder 11.66 10.23 105 498422 20594 62969901
Bradypnoea 11.65 10.23 57 498470 3493 62987002
Osteolysis 11.65 10.23 4 498523 2870 62987625
Fungal rhinitis 11.60 10.23 6 498521 37 62990458
Alpha 1 microglobulin increased 11.55 10.23 7 498520 61 62990434
Somnambulism 11.51 10.23 16 498511 5527 62984968
Injection site nodule 11.51 10.23 8 498519 3827 62986668
Inhibitory drug interaction 11.49 10.23 4 498523 2845 62987650
Cystitis 11.46 10.23 535 497992 54456 62936039
Chronic graft versus host disease 11.44 10.23 5 498522 3097 62987398
Blood bilirubin increased 11.44 10.23 377 498150 36763 62953732
Urine analysis abnormal 11.43 10.23 73 498454 4943 62985552
Nerve injury 11.34 10.23 40 498487 9906 62980589
Left ventricular dysfunction 11.27 10.23 52 498475 11936 62978559
Tooth extraction 11.22 10.23 42 498485 10222 62980273
Eye haemorrhage 11.20 10.23 32 498495 8464 62982031
Pneumonia viral 11.15 10.23 103 498424 7819 62982676
Hip arthroplasty 11.13 10.23 469 498058 47177 62943318
Encephalopathy 11.13 10.23 389 498138 38231 62952264
Acute graft versus host disease 11.11 10.23 11 498516 4417 62986078
Cystic fibrosis 11.11 10.23 6 498521 3290 62987205
Nervous system disorder 11.10 10.23 94 498433 18672 62971823
Haemolysis 11.09 10.23 91 498436 6677 62983818
Necrotic lymphadenopathy 11.09 10.23 7 498520 66 62990429
Infective pulmonary exacerbation of cystic fibrosis 11.06 10.23 34 498493 8783 62981712
Blood immunoglobulin A increased 11.04 10.23 21 498506 757 62989738
Erysipelas 11.00 10.23 29 498498 7876 62982619
Application site rash 10.98 10.23 3 498524 2495 62988000
Laryngospasm 10.98 10.23 5 498522 3023 62987472
Hypoacusis 10.94 10.23 129 498398 24022 62966473
Blood prolactin increased 10.93 10.23 7 498520 3496 62986999
Lung neoplasm malignant 10.88 10.23 100 498427 19533 62970962
Glucose tolerance impaired 10.87 10.23 22 498505 6555 62983940
Diffuse axonal injury 10.87 10.23 8 498519 99 62990396
Aggression 10.84 10.23 125 498402 23373 62967122
Staphylococcal infection 10.80 10.23 244 498283 41012 62949483
Breast cancer metastatic 10.79 10.23 53 498474 11965 62978530
Infusion site discolouration 10.79 10.23 22 498505 835 62989660
Paradoxical drug reaction 10.79 10.23 10 498517 4142 62986353
Abnormal loss of weight 10.75 10.23 18 498509 5764 62984731
Taste disorder 10.75 10.23 63 498464 13599 62976896
Necrosis ischaemic 10.74 10.23 22 498505 838 62989657
Pallor 10.71 10.23 172 498355 30396 62960099
Transfusion-related acute lung injury 10.69 10.23 9 498518 137 62990358
Hypoaesthesia 10.68 10.23 1158 497369 167235 62823260
Orbital compartment syndrome 10.67 10.23 7 498520 71 62990424
Injection site vesicles 10.67 10.23 5 498522 2972 62987523
Granuloma 10.65 10.23 18 498509 5743 62984752
Catheter site bruise 10.63 10.23 16 498511 475 62990020
Asthma-chronic obstructive pulmonary disease overlap syndrome 10.62 10.23 38 498489 2023 62988472
Femoral neck fracture 10.59 10.23 33 498494 8490 62982005
Erythema 10.57 10.23 1213 497314 174538 62815957
Jaw disorder 10.56 10.23 16 498511 5333 62985162
Gout 10.54 10.23 61 498466 13210 62977285
Human herpesvirus 6 infection 10.54 10.23 5 498522 2952 62987543
Anosognosia 10.51 10.23 6 498521 3190 62987305
Hyperhidrosis 10.51 10.23 717 497810 107119 62883376
Stress fracture 10.50 10.23 30 498497 7933 62982562
Cellulitis 10.48 10.23 531 497996 81427 62909068
Bipolar disorder 10.48 10.23 30 498497 7930 62982565
Epilepsy with myoclonic-atonic seizures 10.48 10.23 8 498519 105 62990390
Eating disorder 10.48 10.23 97 498430 18919 62971576
Tumour marker increased 10.40 10.23 14 498513 4901 62985594
Autonomic dysreflexia 10.37 10.23 13 498514 323 62990172
Base excess 10.35 10.23 7 498520 75 62990420
Abdominal pain upper 10.32 10.23 1807 496720 204637 62785858
Haemarthrosis 10.30 10.23 6 498521 3155 62987340
Hysterectomy 10.30 10.23 39 498488 9460 62981035
Left ventricular failure 10.30 10.23 18 498509 5669 62984826
Subdural haematoma 10.27 10.23 68 498459 14260 62976235
Blood immunoglobulin G increased 10.25 10.23 42 498485 2385 62988110
Malignant melanoma 10.25 10.23 50 498477 11306 62979189

FDA Adverse Event Reporting System (Male)

<
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 1333.18 10.35 3240 192174 197122 34564395
Completed suicide 1204.96 10.35 2049 193365 96119 34665398
Exposure to toxic agent 503.76 10.35 292 195122 3383 34758134
Infusion related reaction 474.76 10.35 968 194446 52089 34709428
Blood pressure fluctuation 433.37 10.35 616 194798 24633 34736884
Overdose 386.14 10.35 1253 194161 89806 34671711
Intentional product misuse 346.71 10.35 779 194635 44832 34716685